Denali Therapeutics Inc. (DNLI): Price and Financial Metrics
GET POWR RATINGS... FREE!
DNLI POWR Grades
- Value is the dimension where DNLI ranks best; there it ranks ahead of 68.49% of US stocks.
- DNLI's strongest trending metric is Quality; it's been moving up over the last 31 weeks.
- DNLI's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
DNLI Stock Summary
- DNLI's current price/earnings ratio is 154.12, which is higher than 94.75% of US stocks with positive earnings.
- With a price/sales ratio of 26.23, Denali Therapeutics Inc has a higher such ratio than 91.74% of stocks in our set.
- As for revenue growth, note that DNLI's revenue has grown 1,203.75% over the past 12 months; that beats the revenue growth of 99.12% of US companies in our set.
- Stocks that are quantitatively similar to DNLI, based on their financial statements, market capitalization, and price volatility, are CLGN, BPMC, CARA, GBT, and SGBX.
- Visit DNLI's SEC page to see the company's official filings. To visit the company's web site, go to www.denalitherapeutics.com.
DNLI Price Target
For more insight on analysts targets of DNLI, see our DNLI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $79.89 | Average Broker Recommendation | 1.55 (Moderate Buy) |
DNLI Stock Price Chart Interactive Chart >
DNLI Price/Volume Stats
| Current price | $70.01 | 52-week high | $93.94 |
| Prev. close | $73.73 | 52-week low | $22.36 |
| Day low | $70.01 | Volume | 1,531 |
| Day high | $70.01 | Avg. volume | 572,971 |
| 50-day MA | $61.04 | Dividend yield | N/A |
| 200-day MA | $59.95 | Market Cap | 8.48B |
Denali Therapeutics Inc. (DNLI) Company Bio
Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.
Latest DNLI News From Around the Web
Below are the latest news stories about Denali Therapeutics Inc that investors may wish to consider to help them evaluate DNLI as an investment opportunity.
Former FDA Commissioner Hahn joins VC firm that helped launch ModernaChip Somodevilla/Getty Images News Stephen Hahn, an oncologist who served as FDA commissioner as the Trump administration dealt with the COVID-19 pandemic, has joined venture capital firm Flagship Pioneering as a chief medical officer. Hahn will lead Flagship's Preemptive Medicine and Health Security initiative beginning on Wednesday. More than a... |
Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming?Denali Therapeutics (DNLI) has moved higher as of late, but there could definitely be trouble on the horizon for this company |
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security InitiativeFlagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center. |
Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day BasisRegarding the trend, note that the strongest trend exists on the 50 day timeframe. The post Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News . |
Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report?Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
DNLI Price Returns
| 1-mo | 18.86% |
| 3-mo | 20.29% |
| 6-mo | -20.51% |
| 1-year | 196.53% |
| 3-year | 290.25% |
| 5-year | N/A |
| YTD | -16.42% |
| 2020 | 380.83% |
| 2019 | -15.68% |
| 2018 | 32.10% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching DNLI
Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...